Autopsy report · NCT02282163
Evaluation of Safety and Efficacy of Lumason in Pediatric Echocardiography
Cause of deathSlow enrollment, also regulatory or ethics
“FDA agreed to early termination due to difficulties enrolling patients.”
Life of this trial
- Registered 1 year before it started.
- Ran for about 2 years 10 months before it stopped.
- 13 participants enrolled.
- Results were posted on the registry 1 year 10 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Bracco Diagnostics, Inc
- Sponsor type
- Industry
- Conditions
- Heart Disease
- Interventions
- sulphur hexafluoride lipid-type A microspheres
- Participants
- 13
- Sites
- 2
- Countries
- United States
Trials that died the same way
- Digital Therapeutic vs Educational App for Depression Among Adolescents
“Terminated due to difficulty enrolling patients in the proposed time frame” - One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease
“The study was terminated early due to difficulty in enrollment and lack of clinical study drug access.” - Procalcitonin Level to Discontinue Antibiotics on ICU Patients With no Obvious Site of Infection
“termination due to futility (very slow patient enrollment)” - An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer
“Terminated early due to a lack of efficacy.” - A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
“The study was terminated due to regulatory approval of newer therapeutic options and slower than anticipated accrual.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.